Latest:
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
- About Us
- Advertise / Support
- Editorial Board
- Contact Us
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Contributors
Nina Luker
Latest:
When Faced With Death, Live Life to the Fullest, Says a Cancer Survivor
“I had to choose one of two paths, to become the victim and let the disease control me or take control of the disease and fight for my life. The moment I chose to fight was the moment life opened all of its beauty,” writes a lymphoma survivor.
Igor Makhlin, MD
Latest:
Understanding Treatment Options for ER+/HER2–, ESR1-Mutant Metastatic Breast Cancer
In this on-demand webinar series, Dr. Igor Makhlin discusses personalized treatment options for ER-positive, HER2-negative metastatic breast cancer, including the role of ESR1 mutation testing and targeted therapies like Orserdu.
Kim Margolin, M.D.
Latest:
In Plain English—Intratumoral Injection: Boosting the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses
Intratumoral injection—the boosting of the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses—is a promising treatment method because it’s effective AND it seems to cause fewer toxicities for the patient than combination systemic immunotherapy.